Sorry, you need to enable JavaScript to visit this website.
Skip to main content

All materials and content available on the website are of strictly non-promotional nature and only intended for healthcare professionals (HCPs) practicing in Europe. Kindly note that materials and content are not intended for any specific country and approval conditions for products may vary from country to country. Before prescribing any product, always refer to the approved label in the relevant country and/or the Summary of Product Characteristics.

  • February 06, 2025
  • Testosterone deficiency

Robust evidence on the safety of testosterone replacement therapy in pre-diabetic and diabetic patients

Explore the science
  • February 06, 2025
  • Testosterone deficiency

The TRAVERSE study: redefining what we knew about the safety profile of testosterone replacement therapy

Explore the science
  • February 06, 2025
  • Testosterone deficiency

Depressive syndromes in men with hypogonadism, the impact of testosterone replacement therapy

Explore the science
  • February 06, 2025
  • Testosterone deficiency

Robust evidence on cardiovascular safety of testosterone replacement therapy

Explore the science
  • January 15, 2025
  • Testosterone deficiency

Infographic of testosterone deficiency: its symptoms, diagnosis and treatment

Explore the science
  • January 13, 2025
  • ANCA-associated vasculitis

Explore the unmet needs of AAV patients

Explore the science
  • January 13, 2025
  • ANCA-associated vasculitis

Review a collection of important research on Avacopan

Explore the science
  • November 08, 2024
  • Glomerular Disease

New treatment options for IgAN, along with real-world data for sparsentan: Comprehensive review by Prof. Jörg Latus

Explore the science
  • October 31, 2024
  • Glomerular Disease

Innovative Ansätze zur IgAN-Therapie: Vortrag von Prof. Huynh Do

Explore the science